Skip to main content
. 2018 Nov 28;2018:5196023. doi: 10.1155/2018/5196023

Figure 3.

Figure 3

PDGF BB expression. (a) Faint positivity of PDGF BB (1+) in multinucleated giant cells. Cutaneous scar. PDGF BB x400. (b) Faint positivity of PDGF BB (1+) in macrophages. Cutaneous scar. PDGF BB x400. (c) Intense positivity of PDGF BB (2+) in mesenchymal and endothelial cells. Cutaneous scar. PDGF BB x400. (d). Faint positivity of PDGF BB (1+) in mesenchymal and endothelial cells. Cutaneous scar. PDGF BB x400. (e) PDGF BB expression in mesenchymal cells in cutaneous scars related to localization. (f) PDGF BB expression in endothelial cells in cutaneous scars related to localization. (g) PDGF BB expression in mesenchymal cells in cutaneous scars related to presence of residual neoplasms. (h) PDGF BB expression in endothelial cells in cutaneous scars related to presence of residual neoplasms. (i) PDGF BB expression in macrophages in cutaneous scars related to the presence of residual neoplasms. (j) PDGF BB expression in mesenchymal cells in cutaneous scars related to patient's gender. (k) PDGF BB expression in endothelial cells in cutaneous scars related to patient's gender. (l) PDGF BB expression in macrophages in cutaneous scars related to patient's gender. (m) Oral mucosa scar. Intense positivity of PDGF BB (2+) in macrophages. PDGF BB x400. (n) Oral mucosa scar. Intense positivity of PDGF BB (2+) in endothelial cells. PDGF BB x400.